InflaRx NV stock (NL0012661870): what’s behind the latest trading volatility after Gohibic’s slower ramp?

InflaRx NV has seen renewed share price swings as investors digest the latest revenue trends and commercialization updates for its COVID-19 treatment Gohibic and other anti-inflammatory programs. We explain the business model and key revenue drivers behind the headlines.

InflaRx NV is back in focus on the biotech radar as investors reassess the commercial trajectory for its COVID-19 treatment Gohibic and its broader pipeline of anti-inflammatory antibodies. Recent updates on product sales and cash burn have led to renewed volatility in the stock, according to company disclosures and financial press coverage in spring 2025 and early 2026, as summarized by Nasdaq market data as of 03/20/2025 and subsequent company presentations referenced by InflaRx investor materials as of 04/15/2025.

As of: 19.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: InflaRx NV
• Sector/industry: Biotechnology / biopharmaceuticals
• Headquarters/country: Germany (operational headquarters)
• Core markets: Hospital and specialty care markets in the US and Europe
• Key revenue drivers: Gohibic (vilobelimab) and pipeline antibodies targeting immune-driven diseases
• Home exchange/listing venue: Nasdaq (ticker: IFRX)
• Trading currency: USD

InflaRx NV: core business model

InflaRx NV is a clinical-stage biopharmaceutical company focused on developing monoclonal antibodies that modulate the complement system, an important component of innate immunity implicated in severe inflammatory disorders. The company’s lead asset, vilobelimab, is marketed in the United States under the brand name Gohibic for certain hospitalized COVID-19 patients, based on Emergency Use Authorization and subsequent regulatory pathways described in company filings cited by SEC filings as of 04/19/2023.

The scientific approach at InflaRx is centered on C5a inhibition, targeting a potent inflammatory mediator believed to play a role in driving tissue damage during severe infections and autoimmune diseases. By neutralizing C5a, the company aims to blunt the excessive immune response without fully suppressing host defenses, a strategy discussed in more detail in its R&D presentations reported by InflaRx investor materials as of 11/09/2023. This positioning places InflaRx among a niche group of complement-focused biotechnology players.

InflaRx’s business model combines proprietary antibody discovery and development with selective partnerships for commercialization, especially in markets that require significant sales infrastructure such as the United States hospital segment. For Gohibic in COVID-19, InflaRx relies on collaboration with established pharmaceutical distributors and group purchasing organizations, which is a common route for smaller biotechs that lack a large in-house sales force, as discussed in earnings call transcripts referenced by FierceBiotech as of 04/04/2023.

From a financial standpoint, InflaRx remains heavily R&D-driven, with most expenses related to clinical trials, regulatory activities, and manufacturing scale-up rather than broad commercial operations. According to its annual report for 2023, the company reported no sustained profitability and continued to depend on a mix of equity financing and, more recently, early Gohibic revenue to fund operations, as disclosed in its Form 20-F for the year ended December 31, 2023, published by SEC filings as of 04/01/2024.

Main revenue and product drivers for InflaRx NV

The most visible revenue driver for InflaRx today is Gohibic (vilobelimab) for critically ill COVID-19 patients, a segment that has naturally declined compared with the peak of the pandemic but still exists in intensive care units worldwide. In its 2023 annual report, InflaRx highlighted initial revenues from Gohibic in the United States but emphasized that uptake depended on physician awareness, hospital purchasing decisions, and evolving treatment guidelines, all factors that can create quarter-to-quarter volatility in reported sales, as stated in the 2023 Form 20-F available through SEC filings as of 04/01/2024.

Beyond COVID-19, InflaRx is exploring vilobelimab and other complement-targeting antibodies in indications such as pyoderma gangrenosum, hidradenitis suppurativa, and other immune-mediated diseases. These chronic conditions could offer more durable revenue streams than a declining COVID-19 market if the programs succeed in late-stage clinical development. The company’s pipeline chart, presented at various investor conferences, outlines multiple Phase II and exploratory studies that aim to demonstrate efficacy and safety in these dermatologic and systemic conditions, according to slides made available by InflaRx investor materials as of 09/12/2024.

Another revenue-related driver is the company’s ability to secure reimbursement and pricing for Gohibic and potential future products in the US and European markets. Hospital drugs that target relatively small patient populations often rely on premium pricing, which can support meaningful revenues even at modest volumes but may face pressure from payers and cost-effectiveness assessments. InflaRx has flagged in its risk disclosures that changes in reimbursement rules or budget constraints at hospitals could slow adoption, according to the risk factor section of its 2023 annual report published via SEC filings as of 04/01/2024.

Financing strategy is also a key driver, though indirectly, because InflaRx currently reinvests substantially all cash flows into research, clinical trials, and regulatory activities. The company has periodically raised capital through equity offerings and at-the-market programs to maintain a cash runway, a standard approach among Nasdaq-listed development-stage biotech firms. Share issuances can dilute existing shareholders but provide the funds necessary to advance the pipeline, a trade-off that InflaRx discusses in its capital resources section of financial reports summarized by Nasdaq SEC overview as of 05/10/2024.

Why InflaRx NV matters for US investors

For US-based investors, InflaRx offers exposure to a specialized corner of immunology and infectious disease through a Nasdaq-listed ADR structure, which can be traded like any other US stock during regular market hours. The company’s focus on complement biology places it alongside larger players in the immunology space but with a much smaller market capitalization and more concentrated risk, as reflected in its inclusion in biotech-focused indices tracked by US financial portals, according to sector comparisons published by MarketWatch as of 06/05/2024.

The US is also the primary commercial market for Gohibic, meaning that InflaRx’s near-term revenue outlook is closely tied to hospital procurement trends and reimbursement frameworks in the United States. Changes in US healthcare policy, hospital budgets, and pandemic-related treatment protocols can have an outsized impact on the company’s performance compared with its European peers that may rely more on national health systems. As such, InflaRx can be seen as a way to express a view on niche hospital therapeutics in the post-pandemic US environment, as described in commentary on COVID-19 therapeutics demand by Reuters as of 10/26/2023.

Furthermore, InflaRx’s shares tend to react strongly to clinical trial readouts, regulatory updates, and funding announcements, all of which are closely monitored by US retail traders and biotech-focused funds. This event-driven profile may appeal to investors who follow catalysts such as FDA decisions, Phase II or Phase III data releases, and partnership news. However, it also means the stock can be highly volatile around news flow, a characteristic that the company itself highlights in its risk factor discussions, as noted in its regulatory filings available through SEC company overview as of 04/01/2024.

Conclusion

InflaRx NV exemplifies the high-risk, high-uncertainty profile that is typical for smaller, R&D-focused biotech stocks on Nasdaq, with fortunes closely linked to a narrow set of clinical and commercial milestones. The commercialization of Gohibic in the US offers a tangible revenue stream but operates in a shrinking COVID-19 market that may continue to pressure growth and contribute to swings in investor sentiment. At the same time, the broader pipeline in chronic inflammatory diseases provides potential longer-term optionality, contingent on successful trials, regulatory approvals, and reimbursement. For US investors, InflaRx therefore represents a focused bet on complement biology and hospital-based therapeutics, where careful monitoring of cash runway, trial timelines, and policy developments remains central to understanding the stock’s evolving risk–return profile.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.